Ustekinumab treats psoriasis by suppressing RORC and T-box but its suppression of GATA restrains its efficacy
Braz. J. Pharm. Sci. (Online)
;
54(4): e17349, 2018. tab, graf
Artigo
em Inglês
| LILACS
| ID: biblio-1001566
ABSTRACT
Psoriasis is a T-cell mediated disease that involves IL-23/Th17 and IL-12/Th1 axes. Ustekinumab, a fully human monoclonal antibody targeting the p40 subunit of both IL-12 and IL-23, has proven to be efficient and safe for treating patients with psoriasis. Yet, there have been no reports with human skin/blood samples that would elucidate the molecular mechanisms by which ustekinumab calms psoriasis skin lesions. To investigate the efficacy and molecular pathway (RORC, t-BOX and GATA) of ustekinumab in treating patients with psoriasis skin lesions. A total of 30 patients with psoriasis were randomized into placebo group and treatment group. PASI of each patient was calculated at 0, 12 and 24 weeks post-treatment. The mRNA levels of RORC, t-BOX and GATA in peripheral blood mononuclear cells separated from patients' whole blood were analyzed using qPCR. Decreased mRNA of RORC, t-BOX and GATA were observed after continuous injections, indicating that ustekinumab exerts its effect by interacting with these molecules; while no significant difference in foxp3 mRNA levels were found between placebo group and treatment group.
Texto completo:
DisponíveL
Índice:
LILACS (Américas)
Assunto principal:
Psoríase
/
Eficácia
/
Ustekinumab
Tipo de estudo:
Ensaio Clínico Controlado
Limite:
Adolescente
/
Adulto
/
Idoso
/
Feminino
/
Humanos
/
Masculino
Idioma:
Inglês
Revista:
Braz. J. Pharm. Sci. (Online)
Assunto da revista:
Farmacologia
/
Teraputica
/
Toxicologia
Ano de publicação:
2018
Tipo de documento:
Artigo
País de afiliação:
China
Instituição/País de afiliação:
Ningbo Medical Center Lihuili Hospital/CN
/
Shan Dong Yan Tai Nursing School/CN
/
Zhejiang University School of Medicine/CN
Similares
MEDLINE
...
LILACS
LIS